Medical technology company GE HealthCare (Nasdaq:GEHC) confirmed on Monday that it has completed its acquisition of Sumitomo Chemical's 50% stake in Nihon Medi-Physics Co Ltd (NMP), giving it full ownership of the Tokyo-based radiopharmaceutical company.
NMP develops and manufactures proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging to detect and diagnose diseases.
Founded in 1973, NMP generated JPY28.2bn (approximately USD183m) in revenue in 2023.
NMP's portfolio includes GE HealthCare radiopharmaceuticals used across neurology, cardiology and oncology. The acquisition allows NMP to enhance patient access to next-generation radiopharmaceuticals under the GE HealthCare umbrella.
Kevin O'Neill, president and CEO of GE HealthCare's Pharmaceutical Diagnostics segment, will assume the role of president of NMP. GE HealthCare expects the transaction to be neutral to adjusted EPS in year one and accretive thereafter.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis